Self-reported use of natural health products: A cross-sectional telephone survey in older Ontarians

Levine, Mitchell; Xu, Shuang; Gaebel, Katherine; Brazier, Nicole C.; Bédard, Michel; Brazil, Kevin; Lohfeld, Lynne; MacLeod, Stuart

doi:10.1016/j.amjopharm.2009.12.003

Cited by 34 publications

(33 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies also demonstrate the infrequency of mental health-related CAM service use relative to overall CAM service use. The relatively high rates of mental health-related CAM product use among older adults in our sample are to be expected given high rates of CAM product use for all purposes among older adults, estimated at 27.4% in an American sample of adults 75 years and older (Nahin et al, 2006), 19.1% in a Swedish sample of adults aged 60 years and older (Sjernberg et al, 2006), and 51% in an Ontario sample of adults aged 60 and older (Levine, 2009). Logistic regression analyses for predictors of use of conventional psychoactive medications commonly used for depression and anxiety and alternative products used for mental health health conditions in a nationally representative American survey, 9.8% reported a formal, paid visit to a CAM provider in the last year and only 4.5% reported such a visit specifically to treat their mental health condition (Druss and Rosenheck, 2000).…”

Section: Discussionmentioning

confidence: 83%

Age-related patterns in mental health-related complementary and alternative medicine utilization in Canada

Crabb

Hunsley

2010

Int. Psychogeriatr.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 83%

Age-related patterns in mental health-related complementary and alternative medicine utilization in Canada

Crabb

Hunsley

2010

Int. Psychogeriatr.

View full text Add to dashboard Cite

show abstract

“…The Adverse Event Reporting System database maintained by the Food and Drug Administration noted 580, 904 adverse event reports for drugs and therapeutic biologic products in 2009, more than double the number of such reports in 2001 and 10% more than in 2008 1 . The increasing use of pharmacologic therapy along with over‐the‐counter (OTC) medications and herbal supplements 2,3 may expose patients to the risk of potential drug–drug interactions (DDIs) when more than one drug is metabolized via the cytochrome (CYP) 450 enzyme system. A drug–drug exposure (DDE) occurs when multiple CYP450‐metabolized agents are taken concurrently, but the relationship between DDE and DDI remains to be elucidated, in that not all patients exposed to multiple CYP450‐metabolized drugs will experience a DDI.…”

Section: Introductionmentioning

confidence: 99%

Exposure to Potential CYP450 Pharmacokinetic Drug–Drug Interactions among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions

et al. 2010

View full text Add to dashboard Cite

Abstract:Patients taking more than one drug metabolized through the cytochrome P450 (CYP450) enzyme system experience a drug-drug exposure (DDE), which puts them at risk for a potential pharmacokinetic drug-drug interaction (DDI), defined as two or more drugs interacting in such a way that the effectiveness and/or toxicity of one or all drugs are changed. Any patient subjected to a DDE is at risk for a potentially serious DDI, the epidemiology of which has not been thoroughly studied. Many drugs are metabolized primarily via the CYP450 enzyme system, including certain opioids used to manage moderate to severe chronic pain. We conducted a retrospective analysis of a large commercial claims database and a Medicare database to assess the prevalence of DDEs among patients with osteoarthritis taking CYP450-metabolized opioids. The overall prevalence of DDEs in this population was 26%, with females more likely to experience DDEs than males (28.4% vs. 21.0%, respectively). The number of unique concurrent prescriptions at baseline, gender, age, and Charlson Comorbidity Index were statistically significant predictors of DDEs (P < 0.05). This study challenged previous assumptions about DDEs in that advanced age was not positively associated with the risk of DDE. However, the number of prescriptions the patient received in the 90-day window prior to the index date was a risk factor. For patients taking at least two medications in the 90-day period prior to the index date, every additional prescription taken increased their risk for a DDE during the observation period by 138% (on average). The risk of DDE during the study period was threefold greater for patients with one medication in the 90-day period before Address correspondence and reprint requests to: Joseph V. Pergolizzi

show abstract

“…Studies reported that CAM use prevalence between 26% and 51% [6,7,14]. In Turkey this rate is between 54.3% and 70% [9,10,15].…”

Section: Discussionmentioning

confidence: 99%

The Use of Complementary and Alternative Medicine in the Patients Who Have Respiratory Disorders in Turkey

Kulakac¹

2016

J Alt Med Res

View full text Add to dashboard Cite

show abstract

Self-reported use of natural health products: A cross-sectional telephone survey in older Ontarians

Cited by 34 publications

References 25 publications

Age-related patterns in mental health-related complementary and alternative medicine utilization in Canada

Age-related patterns in mental health-related complementary and alternative medicine utilization in Canada

Exposure to Potential CYP450 Pharmacokinetic Drug–Drug Interactions among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions

The Use of Complementary and Alternative Medicine in the Patients Who Have Respiratory Disorders in Turkey

Contact Info

Product

Resources

About